Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

The study in Cell highlights microbial load's role in gut microbiome variation, suggesting it as a confounder in disease ...

Stress may be the reason people with obesity are more likely to get other metabolic diseases, such as type 2 diabetes, ...

Metabolic diseases, such as cardiovascular diseases and type 2 diabetes, have become one of the world’s largest public health ...

Ozempic breasts refer to changes in breast size or shape due to weight loss from GLP-1 drugs. Here’s how and why this side ...

According to Dr Rakesh Kumar Prasad, Consultant in Diabetology and Endocrinology at Fortis Hospital, Noida, while not ...

Children who are overweight or obese are at a higher risk of developing chronic health conditions like heart disease and type ...

Researchers discovered that a healthy low-carb diet and time-restricted eating, combined with moderate calorie restriction, ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

Fractyl has nominated its first smart GIP/GLP-1 pancreatic gene therapy lead candidate, RJVA-002, designed for the treatment of obesity. RJVA-002 is a locally administered AAV9 viral vector that ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

New therapies for atherosclerosis, obesity and type 2 diabetes are needed. Thyroid hormone excess has potentially useful effects, including lowering of serum cholesterol and reduction of body fat ...